TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05... Read More

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa’s Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an... Read More

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024 Dermatology Drug Development Summit, Boston,... Read More

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates. TORONTO, ON / ACCESSWIRE / June... Read More

TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS... Read More

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario. Edesa's Chief Executive Officer Par Nijhawan, MD, is... Read More

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management plans to participate in the following upcoming investor conferences: Mintz Conference, Toronto, Canada, April 15, 2024 LSX World Congress, London, UK, April 29-30, 2024, with showcase... Read More

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. The Fireside Chat discussion... Read More

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26 th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa... Read More

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego,... Read More

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business. During the first fiscal quarter, the company secured funding of up to C$23 million from the Canadian... Read More

TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management plans to participate in the 2024 Dermatology Summit on January 7, 2024 as well as in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January... Read More

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the year, Edesa reported favorable results from two clinical studies and achieved multiple... Read More

1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced favorable final results from a Phase 2b dose-ranging clinical study of the company's drug candidate, EB01... Read More

TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the 7 th Annual Dermatology Drug Development Summit in Boston, Mass. on November 1, 2023 at 2:10 p.m. ET. Dr. Nijhawan is expected to present, among other... Read More

TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart). Edesa's monoclonal antibody is currently being evaluated as a... Read More

Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement with Dr. Par... Read More

TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate. Edesa's experimental drug, called EB05 (paridiprubart), represents a new class of... Read More

TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its common shares. The Company's common shares will continue to be traded on The Nasdaq Capital Market under the symbol "EDSA" and will... Read More

Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCESSWIRE / September 28, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the preprint publication of favorable data from a Phase 2... Read More

TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2023 and provided an update on its business. During the fiscal third quarter, the company reported positive results from a university study of its monoclonal antibody,... Read More

TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the Canaccord Genuity 43rd Annual Growth Conference being held in Boston from August 7-10, 2023. The Fireside Chat discussion between Edesa's Chief... Read More

Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study was completed by the... Read More

TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of... Read More

TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2023 and provided an update on its business. During the fiscal second quarter, the company achieved two regulatory milestones, including an agreement with the U.S. Food and Drug... Read More

TORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will join a Canadian delegation of officials and industry participating in Swiss Biotech Day on April 24-25, 2023 in Basel, Switzerland. Attendees who are interested in meeting with the company can utilize the conference... Read More

International name assignment is a key step in Edesa's development and commercialization plans TORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the World Health Organization (WHO) has adopted the international nonproprietary name "paridiprubart" for the company's monoclonal antibody... Read More

TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The Fireside Chat discussion between Edesa's Chief Executive... Read More

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023. The presentation will detail the statistically significant topline results achieved... Read More

28-day survival will be evaluated in ARDS patients hospitalized with Covid-19 Updated protocol approved by study's ethics committee Company exploring pathways for treating general ARDS patients TORONTO, ON / ACCESSWIRE / March 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug... Read More

TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business. During the fiscal first quarter, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Edesa's drug... Read More

Company's biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation. TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has received approval from Health Canada for a Phase 2 clinical study of the company's EB06 monoclonal... Read More

Study successfully identified lowest effective dose 1.0% formulation reached primary endpoint with statistical significance Company preparing for End of Phase 2 meeting with FDA following full analysis TORONTO, ON / ACCESSWIRE / January 17, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced preliminary, topline results from... Read More

Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has received Fast Track designation from the U.S. Food and Drug Administration for its monoclonal antibody... Read More

TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business. During the fiscal year, Edesa reported positive final results from the Phase 2 part of a Phase 2/3 study of its monoclonal antibody... Read More

TORONTO, ON / ACCESSWIRE / December 2, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Medical Dermatology, Opthalmology & Medtech Conference. The panel discussion is scheduled to... Read More

Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private placement directly with investors priced at-the-market under the rules of the Nasdaq Stock Market of 2,691,337 common shares, 12-month warrants to purchase up to an aggregate of 1,345,665 common shares and 3-year warrants to... Read More

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Report submitted to FDA Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced final results from the Phase 2 portion of its ongoing Phase... Read More

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022. Edesa Presentation Details Date: September 12, 2022 Time: 10:00 am Eastern Time Presentation Slides: Available in... Read More

Primary Endpoint To Be Reached Within 30 Days, With Topline Data Available by End of Year Company Evaluating Partnership and Out-Licensing Opportunities Outside North America for Its First-in-Class, Anti-Inflammatory Drug Candidate Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient recruitment has been completed for a... Read More